Oncology Biomarkers Market Top Driving Factors and Future Trends 2022
According to research report the global Oncology Biomarkers Market to reach USD 20.4 billion by 2022. and is estimated to grow at a CAGR of 12.2% during the forecast period. Ask for PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202 The increasing prevalence of cancer, rising government support for research on cancer biomarkers, growing use of biomarkers in drug discovery and development, and increasing use of biomarker tests for diagnostic purposes are the major factors that are driving the growth of this market. The major players operating in the cancer biomarkers market are Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson and Company (US), and Hologic (US). The breast cancer segment accounted for the largest share of the cancer biomarkers market in 2016 Based on cancer type, the cancer biomarkers market is segmented into breast, lung, colore...